Compare BH & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BH | LENZ |
|---|---|---|
| Founded | 1934 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 931.9M | 852.0M |
| IPO Year | N/A | 2021 |
| Metric | BH | LENZ |
|---|---|---|
| Price | $299.34 | $30.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $56.25 |
| AVG Volume (30 Days) | 103.0K | ★ 1.3M |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.91 | N/A |
| Revenue | ★ $386,507,000.00 | $17,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $285.82 |
| P/E Ratio | $441.44 | ★ N/A |
| Revenue Growth | ★ 6.87 | N/A |
| 52 Week Low | $195.05 | $16.54 |
| 52 Week High | $381.83 | $50.40 |
| Indicator | BH | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 51.01 |
| Support Level | $266.53 | $27.44 |
| Resistance Level | $306.88 | $32.13 |
| Average True Range (ATR) | 18.00 | 2.17 |
| MACD | -1.60 | 0.99 |
| Stochastic Oscillator | 44.23 | 79.04 |
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.